A randomized placebo‐controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis von Cudkowicz, Merit E., Lindborg, Stacy R., Goyal, Namita A., Miller, Robert G., Burford, Matthew J., Berry, James D., Nicholson, Katharine A., Mozaffar, Tahseen, Katz, Jonathan S., Jenkins, Liberty J., Baloh, Robert H., Lewis, Richard A., Staff, Nathan P., Owegi, Margaret A., Berry, Donald A., Gothelf, Yael, Levy, Yossef S., Aricha, Revital, Kern, Ralph Z., Windebank, Anthony J., Brown, Robert H.

Volltext

Long term beneficial effect of neurotrophic factors-secreting mesenchymal stem cells transplantation in the BTBR mouse model of autism von Perets, Nisim, Segal-Gavish, Hadar, Gothelf, Yael, Barzilay, Ran, Barhum, Yael, Abramov, Natalie, Hertz, Stav, Morozov, Darya, London, Michael, Offen, Daniel

Volltext

Evaluation of neurotrophic factor secreting mesenchymal stem cells in progressive multiple sclerosis von Cohen, Jeffrey A, Lublin, Fred D, Lock, Christoper, Pelletier, Daniel, Chitnis, Tanuja, Mehra, Munish, Gothelf, Yael, Aricha, Revital, Lindborg, Stacy, Lebovits, Chaim, Levy, Yossef, Motamed Khorasani, Afsaneh, Kern, Ralph

Volltext

miRNA profiling of NurOwn®: mesenchymal stem cells secreting neurotrophic factors von Gothelf, Yael, Kaspi, Haggai, Abramov, Natalie, Aricha, Revital

Volltext

Safety of repeated transplantations of neurotrophic factors-secreting human mesenchymal stromal stem cells von Gothelf, Yael, Abramov, Natalie, Harel, Adrian, Offen, Daniel

Volltext

Safety and Clinical Effects of Mesenchymal Stem Cells Secreting Neurotrophic Factor Transplantation in Patients With Amyotrophic Lateral Sclerosis: Results of Phase 1/2 and 2a Clin... von Petrou, Panayiota, Gothelf, Yael, Argov, Zohar, Gotkine, Marc, Levy, Yossef S, Kassis, Ibrahim, Vaknin-Dembinsky, Adi, Ben-Hur, Tamir, Offen, Daniel, Abramsky, Oded, Melamed, Eldad, Karussis, Dimitrios

Volltext

NurOwn, phase 2, randomized, clinical trial in patients with ALS: Safety, clinical, and biomarker results von Berry, James D, Cudkowicz, Merit E, Windebank, Anthony J, Staff, Nathan P, Owegi, Margaret, Nicholson, Katherine, McKenna-Yasek, Diane, Levy, Yossef S, Abramov, Natalie, Kaspi, Haggai, Mehra, Munish, Aricha, Revital, Gothelf, Yael, Brown, Robert H

Volltext

Addressing heterogeneity in amyotrophic lateral sclerosis CLINICAL TRIALS von Goyal, Namita A., Berry, James D., Windebank, Anthony, Staff, Nathan P., Maragakis, Nicholas J., Berg, Leonard H., Genge, Angela, Miller, Robert, Baloh, Robert H., Kern, Ralph, Gothelf, Yael, Lebovits, Chaim, Cudkowicz, Merit

Volltext

Molecular Characterization of VEGF Secretion by MSC-NTF Cells (NurOwn®): Therapeutic Implications in ALS (P5.2-081) von Kaspi, Haggai, Aricha, Revital, Abramov, Natalie, Gothelf, Yael, Lebovits, Chaim, Petroziello, Joseph, Levy, Yossef, Kern, Ralph

Volltext

CSF biomarkers evaluated by principal component analysis in a NurOwn Phase 3 clinical trial (P1-1.Virtual) von Berry, James, Cudkowicz, Merit, Brown, Robert, Aricha, Revital, Kern, Ralph, Windebank, Anthony, Staff, Nathan, Goyal, Namita, Miller, Robert, Katz, Jonathan, Burford, Matthew, Levy, Yossef, Lebovits, Chaim, Gothelf, Yael, Boulanger, Bruno, Mehra, Munish, Lindborg, Stacy

Volltext

Debamestrocel multimodal effects on biomarker pathways in amyotrophic lateral sclerosis are linked to clinical outcomes von Lindborg, Stacy R, Goyal, Namita A, Katz, Jonathan, Burford, Matthew, Li, Jenny, Kaspi, Haggai, Abramov, Natalie, Boulanger, Bruno, Berry, James D, Nicholson, Katharine, Mozaffar, Tahseen, Miller, Robert, Jenkins, Liberty, Baloh, Robert H, Lewis, Richard, Staff, Nathan P, Owegi, Margaret Ayo, Dagher, Bob, Blondheim-Shraga, Netta R, Gothelf, Yael, Levy, Yossef S, Kern, Ralph, Aricha, Revital, Windebank, Anthony J, Bowser, Robert, Brown, Jr, Robert H, Cudkowicz, Merit E

Volltext

NurOwn® Phase 2 ALS Trial: ALSFRS-R Improvement is Reflected in Subscale Domains (S38.002) von Kern, Ralph, Cudkowicz, Merit, Berry, James, Windebank, Anthony, Staff, Nathan, Owegi, Margaret, Lebovits, Chaim, Gothelf, Yael, Brown, Robert

Volltext

Addressing heterogeneity in amyotrophic lateral sclerosis CLINICAL TRIALS von Goyal, Namita A, Berry, James D, Windebank, Anthony, Nathan, P, Maragakis, Nicholas J, van den Berg, Leonard H, Genge, Angela, Miller, Robert, Baloh, Robert H, Kern, Ralph, Gothelf, Yael, Lebovits, Chaim, Cudkowicz, Merit

Volltext

MODULATION OF CSF miRNAs IN ALS PHASE 2 STUDY PARTICIPANTS TREATED WITH MSC-NTF CELLS (NUROWN®) (S25.005) von Aricha, Revital, Kaspi, Haggai, Cudkowicz, Merit, Berry, James, Windebank, Anthony, Staff, Nathan, Owegi, Margaret, Levy, Yossef, Lebovits, Chaim, Brown, Robert, Gothelf, Yael, Kern, Ralph

Volltext

Autologous Transplantation of Mesenchymal Stem Cells Secreting Neurotrophic Factors (Nurown™) In ALS: Results of a Phase 2 Clinical Trial (P2.059) von Petrou, Panayiota, Gotkine, Marc, Gothelf, Yael, Levy, Yossef, Offen, Daniel, Vaknin-Dembinsky, Adi, Argov, Zohar, Ben-Hur, Tamir, Melamed, Eldad, Karussis, Dimitrios

Volltext

NurOwn™: mesenchymal stem cells secreting neurotrophic factors. An autologous cell therapy in clinical trials for ALS von Gothelf, Yael, Levy, Yossef, Burshtein, Alex, Abramov, Natalie, Sulliman, Shimrit, Fiorino, Tony

Volltext

Update on clinical trials with autologous bone marrow-derived mesenchymal stem cells secreting neurotrophic factors (MSC-NTF) in patients with amyotrophic lateral sclerosis (ALS) von Gothelf, Yael, Petrou, Panayota, Gotkine, Marc, Vaknin-Dembinsky, Adi, Levy, Yossef, Offen, Dani, Ben-Hur, Tamir, Melamed, Eldad, Karussis, Dimitri

Volltext

5′ upstream sequences of MyD88, an IL-6 primary response gene in M1 cells: detection of functional IRF-1 and Stat factors binding sites von Harroch, Sheila, Gothelf, Yaël, Revel, Michel, Chebath, Judith

Volltext

METHOD OF QUALIFYING CELLS von LEVY, Yosef, GOTHELF, Yael

Volltext bestellen

PHARMACEUTICAL COMPOSITION COMPRISING BONE-MARROW DERIVED MESENCHYMAL STEM CELLS von LEVY, YOSEF, GOTHELF, YAEL

Volltext bestellen